Eider Egilegor

504 citations
5 papers · 422 indexed · h-index 5
Topics
Inflammasome and immune disorders (2 papers)Genital Health and Disease (1 paper)Angiogenesis and VEGF in Cancer (1 paper)
Partner nations
SpainUnited States

In The Last Decade

Eider Egilegor

5 papers receiving 414 citations

Peers

Eider Egilegor
Comparison fields: 5 of 60
  • Molecular Biology 219
  • Oncology 150
  • Immunology 143
  • Hepatology 83
  • Cancer Research 57
Replace Seo Hee Nam with:
Seo Hee Nam South Korea
Xiaoping He United States
Enrico Jandt Germany
Gaël S. Roth France
Wenbing Sun China
Xiaoqian Jing China
Yibin Ren China
Caren Jayasinghe Germany
Eider Egilegor relative to Seo Hee Nam South Korea Seo Hee Nam's profile →
Citations per field
00.5×1.5×2.4×
Seo Hee Nam · 1×
Citations per year

Countries citing papers authored by Eider Egilegor

Since Specialization
Citations

This map shows the geographic impact of Eider Egilegor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eider Egilegor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eider Egilegor more than expected).

Fields of papers citing papers by Eider Egilegor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eider Egilegor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eider Egilegor. The network helps show where Eider Egilegor may publish in the future.

Co-authorship network of co-authors of Eider Egilegor

This figure shows the co-authorship network connecting the top 25 collaborators of Eider Egilegor. A scholar is included among the top collaborators of Eider Egilegor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eider Egilegor. Eider Egilegor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

5 of 5 papers shown
#WorkIndexed citations
1 47
2 101
3 34
4 153
5
Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium.
87

About Eider Egilegor

Eider Egilegor is a scholar working on Geriatrics and Gerontology, Hepatology and Immunology, having authored 5 papers that have together received 422 indexed citations. Recurring topics across this work include Inflammasome and immune disorders (2 papers), Genital Health and Disease (1 paper) and Angiogenesis and VEGF in Cancer (1 paper). The work is most often cited by research in Hepatology (83 citations), Immunology (143 citations) and Geriatrics and Gerontology (25 citations). Eider Egilegor has collaborated with scholars based in Spain and United States. Frequent co-authors include Clarisa Salado, Fernando Vidal‐Vanaclocha, María Valcárcel, Lorea Mendoza, Elvira Olaso, Charles A. Dinarello, Virginia Franco‐Gutiérrez, Scott L. Friedman, Pau Sancho‐Bru and Teresa Carrascal. Their work appears in journals such as Hepatology, Cancer Research and Cancer and Metastasis Reviews.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026